As founders, we work side-by-side with our entrepreneurs to
build companies around innovative science.
Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016
Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)
Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders
Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases
Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)
Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)
Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016
Re-dosable, titratable genetic
medicines with drug-like properties
for patients with genetic diseases
Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)
Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)
Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)
Discovering and developing
novel integrin antagonists for
serious fibrotic diseases
Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019
Novel MetAP2 therapeutics to transform
complex metabolic disorders –
IPO June 2014 (NASDAQ: ZFGN)
Advancing targeted protein
degradation to target previously
“undruggable” disease pathways
